Cost-utility analysis and budget impact analysis of pegvisomant for the treatment of adult patients with acromegaly in Poland
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2018, Vol 2, Issue 2
Abstract
Background: The aim of this publication was to evaluate the cost-effectiveness and financial consequences of pegvisomant (PEG) in the treatment of adult patients with acromegaly, who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues (SSA) did not normalize IGF-1 concentrations or was not tolerated compared with SSA continuation. Methods: The Markov model constructed in TreeAge Pro with 45-year time horizon was used in the cost-utility analysis (CUA). Quality adjusted life years (QALY) were used as the measure of effectiveness. CUA was conducted from the perspective of the public payer for health services (Polish National Health Fund, PNHF) and from the patient’s and PNHF’s perspective. Budget impact analysis was performed in a 3-year time horizon from PNHF’s perspective. Two scenarios were compared: “present”, without reimbursement of PEG; “new”, after reimbursement of PEG. Results: The cost of gaining an additional QALY by replacing SSA with PEG is equal 742,724 PLN/ 714,800 PLN (172 470 €/ 165 986 €) from PNHF/PNHF+patient perspective. The annual expenditure of the PNHF’s budget in the first three years would increase by approximately 11.95 million PLN in the first, 26.39 million PLN in the second and 26.5 million in the third year of PEG reimbursement. Conclusion: The creation of drug program for acromegalic patients, in which reimbursement of PEG will be provided, will significantly influence the prognosis, course of the disease and improve the patient’s quality of life.
Authors and Affiliations
Ewa Borowiack, Magdalena Marzec, Anna Nowotarska, Katarzyna Policht, Małgorzata Konopka-Pliszka, Joanna Jarosz, Monika Borowiack
Keywords
Related Articles
- EP ID EP532140
- DOI 10.7365/JHPOR.2018.2.3
- Views 69
- Downloads 0
Assessment of quality of life, disease activity and productivity loss of patients with ulcerative colitis in Poland
Purpose: The aim of the study was to assess the relationship between the disease activity and both indirect costs and health-related quality of life among ulcerative colitis (UC) patients in Poland. Methods: A questionn...
Real World Evidence (RWE) and Orphan drug policies in selected Central and Eastern European (CEE) Countries
The rationale for the initial project performed in the Central and Eastern European countries (CEE) was to assess and to share information from the region regarding drug policies. With this special cross countries compar...
The adaptation of new methodology of quality of life assessment in patients with thrombocytopenia in Ukraine as a result of Polish-Ukrainian collaboration
Objective. Our aim was linguistic adaptation the Thrombocytopenia Symptoms and their Impact on patients Daily Activities Assessment Vignette (TSIDAV) into Ukrainian. Methods: In the translation process were involved two...
Reimbursement and value assessment frameworks: ensuring patients’ access to asthma medicines in Ukraine
Background. Health technology assessment (HTA) introduction and implementation for development of the National List of Essential Medicines (NLEM) took place in Ukraine in 2016 in the context of National Drug Policy until...
Environmental Determinant of Acute Diarrheal Disease among Under five Children: Unmatched Case Control Study in Babile District, East Hararghe Zone, Oromia Region, East Ethiopia
Introduction: Diarrhea is defined as passing of loose or watery stool for three or more times during a 24 hours period. Diarrhea is one of the leading causes of mortality in developing countries, especially among childre...